Clinical Implications
Prescribing GLP-1 therapies should be part of a comprehensive obesity-management strategy that considers social determinants of health, food environments, and equitable access. It is crucial to balance commercial pressures with public health objectives.
GLP-1 receptor agonists have fundamentally changed the landscape of obesity treatment, prompting the World Health Organization to issue its first global guideline recommending these medications. However, the WHO also underscores the importance of equitable access to GLP-1 therapies, coupled with necessary policy changes to combat unhealthy food environments, raising concerns about how commercial interests may influence the future of obesity treatment.
A recent editorial in Science indicates that the expanding
Fuente: https://www.epocrates.com/online/article/could-the-glp-1-boom-deepen-health-inequities
Join the doctors who get the most relevant medical news, curated by specialty, every week — no spam, unsubscribe anytime.
